Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

15. Juni 2018 11:30 ET | Quelle: Nohla Therapeutics

Nohla Announces Presentation of Dilanubicel (NLA101) Data at EHA Annual Meeting Showcasing Excellent Long-term Survival Outcomes

SEATTLE, June 15, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...
06. Juni 2018 13:00 ET | Quelle: Nohla Therapeutics

Nohla Receives EMA PRIME Designation for Dilanubicel (NLA101) to Treat Hematopoietic Stem Cell Transplant Patients

SEATTLE, June 06, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...
17. Mai 2018 13:00 ET | Quelle: Nohla Therapeutics

Nohla Announces EHA Abstract Acceptance on Dilanubicel (NLA101) Off-the-Shelf Cell Therapy Showing Excellent Long-term Survival Outcomes

SEATTLE, May 17, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignances and other critical diseases,...